Press

Acarix announces the last patient included in Dan-NICAD
II study

 

After the inclusion of 1726 patients, Acarix announces that the last patient has been included in Dan-NICAD II, a study of noninvasive diagnostic testing in patients with suspected Coronary Artery Disease (CAD).

PR_Acarix_Dan-NICAD II_ENG

PM_Acarix_Dan-NICAD II_SVE

 

 

 

 

 

 

 

About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se) is Certified Advisor of Acarix.

For more information, please visit www.acarix.com.